FY2025 · ended Dec 31, 2025 · Revenue $1.30M, +550.0% YoY · Filed Mar 19, 2026
Inhibrx Biosciences, Inc. (INBX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.3 million and a net loss of $140.1 million. Free cash flow was -$129.8 million. As of Jun 30, 2026 it held $133.3 million in cash and investments and $181.6 million in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-138.18M
+15.6% vs year-ago TTM
Operating cash flow (TTM)
$-131.89M
+5.7% vs year-ago TTM
Free cash flow (TTM)
$-131.90M
+5.9% vs year-ago TTM
EPS (TTM)
$-8.88
+16.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.61M
+0.9% vs prior year
Net cash
$-48.28M
as of Jun 30, 2026
Operating margin
-10386.5%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2007919
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $1.3M | $200,000 |
| Operating income | -$135.0M | -$331.4M |
| Net income | -$140.1M | $1.7B |
| Diluted EPS | -$9.04 | $112.62 |
| Operating cash flow | -$129.8M | -$194.4M |
| Free cash flow | -$129.8M | -$197.0M |
| Total assets | $146.5M | $180.8M |
| Total liabilities | $138.5M | $47.2M |
| Stockholders' equity | $8.0M | $133.6M |
| Cash and investments | $124.2M | $152.6M |
| Total debt | $107.0M | $8.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
All 158 Inhibrx Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.